ValuEngine Lowers United Therapeutics (NASDAQ:UTHR) to Buy

ValuEngine downgraded shares of United Therapeutics (NASDAQ:UTHR) from a strong-buy rating to a buy rating in a report published on Friday, February 2nd.

A number of other analysts also recently commented on UTHR. HC Wainwright reiterated a hold rating and issued a $95.00 target price on shares of United Therapeutics in a report on Thursday, October 26th. Credit Suisse Group reissued an underperform rating and issued a $118.00 target price on shares of United Therapeutics in a research report on Thursday, January 18th. BidaskClub downgraded shares of United Therapeutics from a hold rating to a sell rating in a research report on Tuesday, January 16th. TheStreet raised shares of United Therapeutics from a c+ rating to a b rating in a research report on Friday, December 15th. Finally, Cowen reissued a hold rating and issued a $129.00 target price on shares of United Therapeutics in a research report on Friday, October 27th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. United Therapeutics presently has an average rating of Hold and an average price target of $140.27.

Shares of United Therapeutics (UTHR) opened at $128.71 on Friday. United Therapeutics has a fifty-two week low of $112.01 and a fifty-two week high of $169.89. The company has a market cap of $5,561.69, a P/E ratio of 11.35 and a beta of 1.26.

In other news, Director Christopher Causey sold 580 shares of the business’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $134.72, for a total value of $78,137.60. Following the completion of the sale, the director now directly owns 1,555 shares in the company, valued at $209,489.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Martine A. Rothblatt sold 7,061 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $121.12, for a total transaction of $855,228.32. The disclosure for this sale can be found here. Insiders sold 10,136 shares of company stock valued at $1,248,989 over the last three months. Insiders own 7.80% of the company’s stock.

Several institutional investors have recently modified their holdings of UTHR. State Street Corp raised its stake in United Therapeutics by 0.9% during the 2nd quarter. State Street Corp now owns 2,014,506 shares of the biotechnology company’s stock valued at $261,345,000 after purchasing an additional 17,179 shares during the last quarter. Acadian Asset Management LLC raised its stake in United Therapeutics by 2.4% during the 4th quarter. Acadian Asset Management LLC now owns 1,121,068 shares of the biotechnology company’s stock valued at $165,861,000 after purchasing an additional 26,122 shares during the last quarter. Old Mutual Global Investors UK Ltd. raised its stake in United Therapeutics by 30.3% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 970,846 shares of the biotechnology company’s stock valued at $113,773,000 after purchasing an additional 225,953 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in United Therapeutics by 9.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 798,093 shares of the biotechnology company’s stock valued at $93,531,000 after purchasing an additional 71,333 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in United Therapeutics by 2.0% during the 4th quarter. Wells Fargo & Company MN now owns 744,312 shares of the biotechnology company’s stock valued at $110,120,000 after purchasing an additional 14,593 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/11/united-therapeutics-uthr-stock-rating-lowered-by-valuengine.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply